Daniel Arber to Risk Assessment
This is a "connection" page, showing publications Daniel Arber has written about Risk Assessment.
Connection Strength
0.082
-
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Jul 08; 9(13):3370-3380.
Score: 0.033
-
TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management. Am J Hematol. 2025 Jun; 100 Suppl 4:88-115.
Score: 0.033
-
Primary Gastric Hodgkin's Lymphoma: An Extremely Rare Entity and A Diagnostic Challenge. Dig Dis Sci. 2015 Oct; 60(10):2923-6.
Score: 0.016